Healthcare analytics provider LOGEX and P95, a company specialized in epidemiology of infectious diseases, have signed an agreement to jointly create an international infectious disease observatory. The goal of the observatory is to offer an international platform for research of infectious diseases like COVID-19, RSV, Influenza, Norovirus and other infections that may have a significant health impact in Europe. Additionally, the platform will be used for assessing the impact, effectiveness and safety of vaccines or other pharmaceutical health interventions.
The observatory will initially include 20 hospitals in five European countries. The first proof-of-concept studies will be presented at the end of 2023. The observatory’s name, ARWEN ID, is derived from the Actionable Real World Evidence Network (ARWEN) and its focus on infectious diseases (IDs).
Find P95 on LinkedIn to follow the progress of this new joint effort.
About P95
P95 is a full-service CRO specializing in clinical trials, epidemiology, and real-world evidence. With deep expertise in infectious disease and global health, P95 provides tailored solutions across all phases of clinical research. P95’s global reach, coupled with regional specialization in Africa, Low- and Middle-Income Countries, and beyond ensure impactful outcomes in even the most challenging environments.
About LOGEX
For more information on LOGEX, visit LOGEX.com
About ARWEN
For more information ARWEN, visit arwen.eu
0 Comments